Accord Backed In EU For Trastuzumab And Apixaban

Part Of May Meeting of EMA’s CHMP

 
• By Dean Rudge

Accord Healthcare is looking to breaking into the crowded market for biosimilar trastuzumab in the EU, after partner Henlius’ application was backed by the EMA’s CHMP. Meanwhile, a recommendation for a generic to the Eliquis anticoagulant was also forthcoming from the committee.

Green_Light
Accord's applications for biosimilar trastuzumab and generic apixaban have been greenlit • Source: Shutterstock

More from Biosimilars

More from Products